Testing effectiveness (Phase 2)UnknownNCT04940637What this trial is testingUNITO-001- Study in HRR/PDL1 Positive MPM/NSCLCWho this might be right forLung CancerMesothelioma University of Turin, Italy 70
Testing effectiveness (Phase 2)WithdrawnNCT04470674What this trial is testingStudy of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC PatientsWho this might be right forLung CancerNon-small Cell Lung CancerPD-L1 Gene Mutation+1 more Shirish M Gadgeel
Large-scale testing (Phase 3)Looking for participantsNCT06119581What this trial is testingFirst-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerWho this might be right forCarcinoma, Non-Small-Cell LungNeoplasm Metastasis Eli Lilly and Company 1,264
Testing effectiveness (Phase 2)UnknownNCT03491345What this trial is testingK-Basket, Avelumab, Biomarker-driven, Advanced Solid TumorWho this might be right forPD-L1 Positive Mutation TumorEBV Positive Mutation TumorMSI-H Mutation Tumor+1 more Yonsei University 60
Not applicableUnknownNCT05527808What this trial is testingA Single-arm Exploratory Study of Neoadjuvant TherapyWho this might be right forLung Adenocarcinoma Jun Liu 28
Testing effectiveness (Phase 2)UnknownNCT04023916What this trial is testingSintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.Who this might be right forDiffuse Large B-Cell LymphomaSintilimabTP53 Mutation Chinese Academy of Medical Sciences 30
Testing effectiveness (Phase 2)UnknownNCT05266937What this trial is testingAtezolizumab Plus CArboplatin Plus Nab-paclitaxelWho this might be right forMetastatic Breast CancerTriple Negative Breast CancerPD-L1 Gene Mutation Consorzio Oncotech 49
Testing effectiveness (Phase 2)UnknownNCT05534113What this trial is testingEnvafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLCWho this might be right forNon-small Cell Lung Cancer The First Affiliated Hospital with Nanjing Medical University 38
Early research (Phase 1)Study completedNCT02027961What this trial is testingPhase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib AloneWho this might be right forMelanoma MedImmune LLC 68
Testing effectiveness (Phase 2)Looking for participantsNCT04585750What this trial is testingThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Who this might be right forAdvanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more PMV Pharmaceuticals, Inc 300
Testing effectiveness (Phase 2)Study completedNCT04426825What this trial is testingAtezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung CancerWho this might be right forCarcinoma, Non-Small-Cell Lung Hoffmann-La Roche 23
Not applicableUnknownNCT05110950What this trial is testingEndobronchial Ultrasound Needle Aspiration With and Without SuctionWho this might be right forMediastinal LymphadenopathyHilar LymphadenopathyLymphoma+7 more Università Politecnica delle Marche 306
Early research (Phase 1)Study completedNCT01656642What this trial is testingA Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic MelanomaWho this might be right forMalignant Melanoma Genentech, Inc. 67
Testing effectiveness (Phase 2)WithdrawnNCT05233696What this trial is testingRadiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBCWho this might be right forTriple Negative Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma+2 more University of Colorado, Denver
Testing effectiveness (Phase 2)Looking for participantsNCT06269211What this trial is testingNeoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive ExpressionWho this might be right forCarcinoma, Non-Small-Cell Lung Ruijin Hospital 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT05078931What this trial is testingEvaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC PatientsWho this might be right forNSCLC Shanghai Chest Hospital 35
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06982924What this trial is testingA Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.Who this might be right forEGFR Mutation Positive Advanced Non Small Cell Lung CancerPD-L1 Positive Shanghai Chest Hospital 136
Very early researchLooking for participantsNCT06305962What this trial is testing177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsWho this might be right forPDL1 Gene MutationNon Small Cell Lung CancerSmall Cell Lung Cancer ( SCLC )+6 more Radiopharm Theranostics, Ltd 30
Testing effectiveness (Phase 2)UnknownNCT05004974What this trial is testingSintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung CancerWho this might be right forAdvanced Non Small Cell Lung Cancer The Fourth Affiliated Hospital of Zhejiang University School of Medicine 20